RGEN — Trading Ideas on TradingView

Repligen (RGEN)'s Hidden Value Despite a daily loss of 3.9% and a 3-month loss of 3.4%, Repligen Corp (NASDAQ:RGEN) shows a promising Earnings Per Share (EPS) of 2.42. This raises a compelling question: Is the stock significantly undervalued? Repligen Corp is a leading life sciences company with a global presence. It is renowned for developing and commercializing innovative bioprocessing technologies and systems that enhance efficiencies in manufacturing biological drugs. With a broad customer base ranging from life science companies to global biopharmaceutical companies and contract manufacturers, Repligen markets its products worldwide. The majority of its revenue is generated in North America. With a current stock price of $147.19 per share and a market cap of $8.20 billion, it's critical to compare these figures with the GF Value, which is an estimation of fair value. This comparison will pave the way for a deeper exploration of the company's value. Understanding GF Value The GF Value is a proprietary measure that represents the current intrinsic value of a stock. It's calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates. The GF Value Line gives an overview of the fair value at which the stock should ideally be traded. Repligen (NASDAQ:RGEN) appears to be significantly undervalued. If the stock price is significantly above the GF Value Line, it is overvalued, and its future return is likely to be poor. Conversely, if it is significantly below the GF Value Line, its future return will likely be higher. Given Repligen's current price and market cap, the stock shows every sign of being significantly undervalued. Because Repligen is significantly undervalued, the long-term return of its stock is likely to be much higher than its business growth. Assessing Financial Strength Before investing in a company, it's crucial to assess its financial strength. Investing in companies with poor financial strength carries a higher risk of permanent loss. The cash-to-debt ratio and interest coverage can provide a great insight into a company's financial strength. Repligen has a cash-to-debt ratio of 1.43, which is lower than 59.01% of 832 companies in the Medical Devices & Instruments industry. However, the overall financial strength of Repligen is 8 out of 10, indicating strong financial health.

$rgen ready for break out long

RGEN (update) TARGET UP TO $180 RGEN I had plans to post before but now I want to update this plan separately because it looks better than before. - Cup and Handle pattern (with the right-hand Gap acts as the handle). - Confirm " symmetrical triangle " pattern above the Cup. Rgen buy : $155 Rgen target : $180+ Stop loss : $150 Wish you a good deal !

RGEN BUY OR LONG , TARGET UP TO $180 RGEN confirmed to break out of Coc, with the appearance of Gap on the right instead of the handle (Gap is big support) so you can understand this is the "Cup and Handle" pattern . RGEN buy : $147 +- 0,5 RGEN target : $180 +-1 Stop loss : 10% Wish you good deals!

RGEN - LEAPS & BOUNDs RGEN: Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. RGEN as a mid-cap is new watch and being saved for own watch list and entry steep right now. 2.4B Mkt Cap and similiar EV. BETA 0.71 so great buy and forget stock. Debt low to cash flow. Ownership: 80 Institution, 3 Management and insider trend has been sell. Look at chart and ask why? Q2 Earnings in early Aug. were good, but first time below mkt expectations in awhile....so watching. Q3 E in early Nov-18. Buylongselllong format courtesy of @MarxBabu. Format changed to add 1w MA and add resistance line for optimal entry. Comments & feedback appreciated especially if you understand the technology by Repligen.